Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 272 for:    Recruiting, Not yet recruiting, Available Studies | "Lower Urinary Tract Symptoms"

Prostatic Obstruction Investigation Team Multicenter Study (POInT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03394651
Recruitment Status : Recruiting
First Posted : January 9, 2018
Last Update Posted : November 14, 2018
Sponsor:
Collaborators:
Beijing Hospital
Zhongda Hospital
RenJi Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The Second Hospital of Nanjing Medical University
Shanghai Changzheng Hospital
Third Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital of Suzhou University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Zhujiang Hospital
Zhejiang University
Shanghai Zhongshan Hospital
Xinqiao Hospital of Chongqing
Zhejiang Provincial People’s Hospital
Huashan Hospital
Southwest Hospital, China
First Affiliated Hospital of Fujian Medical University
The First Affiliated Hospital of Beijing University
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Tianjin Medical University Second Hospital
The Third Affiliated Hospital of Beijing University
Jiangsu Provincial People's Hospital
Information provided by (Responsible Party):
Yinghao Sun, Changhai Hospital

Tracking Information
First Submitted Date December 14, 2017
First Posted Date January 9, 2018
Last Update Posted Date November 14, 2018
Actual Study Start Date April 1, 2018
Estimated Primary Completion Date April 1, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: January 8, 2018)
  • The changes of IPSS scores between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided, or 1, 6, 18, 24 months after surgery. ]
    Measured using standard IPSS scoring system
  • The changes of nocturia symptoms between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided, or 1, 6, 18, 24 months after surgery ]
    Measured using standard ICIQ-N-QoL score
  • The changes of erectile function between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided, or 1, 6, 18, 24 months after surgery ]
    Measured using standard IIEF score
  • The changes of maximum flow rate (ml/s) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery ]
    Maximum flow rate will be measured using urinary flow study
  • The changes of post void residual volume (ml) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery ]
    post void residual volume (ml) will be measured using urinary flow study
  • The changes of detrusor pressure at maximum flow rate (cmH2O) between baseline and follow-up [ Time Frame: Measured at baseline (if surgical treatment is required) and 1, 6, 18, 24 months after surgery ]
    It will be measured using pressure-flow study
  • The changes of prostate volume (ml) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months after oral medication treatment ]
    Prostate volume (ml) will be measured using transrectal prostate ultrasound and calculated as: prostate volume (ml) = length (mm) * width (mm) * height (mm) * 0.52
  • The changes of intravesical prostate protrusion (mm) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months after oral medication treatment ]
    Intravesical prostate protrusion (mm) will be measured using transrectal prostate ultrasound and calculated as the distance between the tip of the prostate median lobe and bladder neck
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT03394651 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: January 8, 2018)
  • The changes of Blood pressure between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    systolic pressure/ diastolic pressure in mmHg.
  • The changes of Blood lipid between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    The blood lipid level will be assessed using multiple serum parameters, namely, cholesterol (mmol/L), triglyceride (mmol/L), high-density lipoprotein (mmol/L), low-density lipoprotein (mmol/L), lipoprotein-a (mmol/L)
  • The changes of Blood glucose between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    The blood glucose level will be assessed using multiple serum parameters, namely, fast blood-glucose (mmol/L), glycosylated hemoglobin (%), glycated albumin (%)
  • The changes of Kidney function between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    The kidney function will be assessed using multiple serum and urine parameters, namely, serum creatinine (μmoI/L), cystatin-C (mg/L), eGRF (calculated via both CKD-EPI equation and MDRD equation), BUN (mmol/L), uric acid (μmoI/L), β2-MG (mg/L), NAG (U/L), Na (mmol/L), K (mmol/L), the degree of urine protein
  • The changes of PSA (ng/ml) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    Serum PSA level will be measured to rule out prostate cancer
  • The changes of RBC (/HP) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    Urine RBC will be measured to detect the incidence of urinary tract infection or tumor
  • The changes of WBC (/HP) between baseline and follow-up [ Time Frame: Measured at baseline and 6, 12, 18, 24, 36 months if oral medication is provided or 1, 6, 18, 24 months after surgery. ]
    Urine WBC will be measured to detect the incidence of urinary tract infection
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Prostatic Obstruction Investigation Team Multicenter Study
Official Title The Current Status and Progression of Symptoms and Comorbidities Among Male Lower Urinary Tract Symptoms Patients in China: a Multicenter Study From Prostatic Obstruction Investigation Team (POInT)
Brief Summary The present is a multicenter, observational study organized by the Prostatic Obstruction Investigation Team (POInT), with a main purpose of looking into the current status and symptom progression of male lower urinary tract symptoms patients in China.
Detailed Description Lower urinary tract symptoms (LUTS) is a common medical condition negatively affecting people's quality of life worldwide. LUTS may be caused by structural or functional abnormalities in 1 or more parts of the lower urinary tract, including bladder, prostate, internal and external urethral sphincter and distal urethra. Furthermore, evidence exists to demonstrate that LUTS is associate with lifestyle factors, systemic comorbidities and geriatric diseases, such as smoking, obesity, metabolic syndrome, chronic kidney diseases and chronic obstructive pulmonary disease etc. So far, there is lack of evidence to illustrate the symptom features and comorbidities among Chinese male LUTS patients. Therefore, this multicenter clinical study aims to investigate the present status and symptom progression among male LUTS patients in China.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
blood and urine
Sampling Method Non-Probability Sample
Study Population Chinese male, 45 year or elder, presenting lower urinary tract symptoms.
Condition Lower Urinary Tract Symptoms
Intervention
  • Drug: Oral medications to treat lower urinary tract symptoms
    Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
  • Procedure: Minimal invasive transurethral prostate procedures
    Patients in this group will receive surgical treatment.
Study Groups/Cohorts
  • Oral medication group
    Patients in this group will receive oral medications to treat lower urinary tract symptoms
    Intervention: Drug: Oral medications to treat lower urinary tract symptoms
  • Surgical treatment group
    Patients in this group receive minimal invasive transurethral prostate procedures.
    Intervention: Procedure: Minimal invasive transurethral prostate procedures
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: January 8, 2018)
11500
Original Estimated Enrollment Same as current
Estimated Study Completion Date April 1, 2022
Estimated Primary Completion Date April 1, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Male, 45 years or older.
  2. The presence of lower urinary tract symptoms, i.e. frequency, urgency, urge incontinence, dysuria, post-micturition dribble, etc.
  3. All participants have signed the informed consent form.
  4. Clinical data comes from 23 selected hospitals spread across China.

Exclusion Criteria:

  1. Lower urinary tract symptoms as a result of urethral stricture, stone diseases, chronic prostatitis, space-occupying lesions etc.
  2. Diagnosis or suspicion of renal, ureteral, bladder, prostate, urethral or pelvic tumor.
  3. Known neurogenic or congenital lower urinary tract dysfunction.
  4. Known urinary tract, prostate or pelvic surgical history.
  5. Existence of anatomical abnormalities of the urinary tract (e.g. diverticulum of the bladder or urethra, ectopic ureteral orifice etc.).
  6. The presence of acute conditions, such as, urinary tract infection, fever, heart failure etc.
  7. Patients with poor compliance or cognitive competence.
Sex/Gender
Sexes Eligible for Study: Male
Ages 45 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Qi-Xiang Song, MD, PhD 086-15021223013 rex_song918@qq.com
Contact: Wei Xue, MD, PhD 086-13801931604 uroxuewei@163.com
Listed Location Countries China
Removed Location Countries  
 
Administrative Information
NCT Number NCT03394651
Other Study ID Numbers POINT-2017
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Yinghao Sun, Changhai Hospital
Study Sponsor Changhai Hospital
Collaborators
  • Beijing Hospital
  • Zhongda Hospital
  • RenJi Hospital
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • The Second Hospital of Nanjing Medical University
  • Shanghai Changzheng Hospital
  • Third Affiliated Hospital, Sun Yat-Sen University
  • The First Affiliated Hospital of Suzhou University
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  • Zhujiang Hospital
  • Zhejiang University
  • Shanghai Zhongshan Hospital
  • Xinqiao Hospital of Chongqing
  • Zhejiang Provincial People’s Hospital
  • Huashan Hospital
  • Southwest Hospital, China
  • First Affiliated Hospital of Fujian Medical University
  • The First Affiliated Hospital of Beijing University
  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
  • Tianjin Medical University Second Hospital
  • The Third Affiliated Hospital of Beijing University
  • Jiangsu Provincial People's Hospital
Investigators
Study Chair: Yinghao Sun, MD, PhD Changhai Hospital
Principal Investigator: Wei Xue, MD, PhD RenJi Hospital
Principal Investigator: Qi-Xiang Song, MD,PhD Changhai Hospital
PRS Account Changhai Hospital
Verification Date November 2018